Shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) saw unusually-strong trading volume on Monday after UBS Group raised their price target on the stock from $21.00 to $22.00. UBS Group currently has a buy rating on the stock. Approximately 17,251 shares were traded during mid-day trading, an increase of 41% from the previous session’s volume of 12,207 shares.The stock last traded at $18.60 and had previously closed at $18.24.
Separately, William Blair upgraded shares of Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a research note on Tuesday, November 19th.
Get Our Latest Analysis on TLX
Telix Pharmaceuticals Limited American Depositary Shares Price Performance
Telix Pharmaceuticals Limited American Depositary Shares Company Profile
Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.
Further Reading
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- Profitably Trade Stocks at 52-Week Highs
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Do ETFs Pay Dividends? What You Need to Know
- What Does the Future Hold for Eli Lilly?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
